文献速递腹部技术与安全CT

长效可重复奥曲肽治疗晚期胃肠胰神经内分泌肿瘤的CT疗效评估:最佳尺寸变化阈值是什么

CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
PubMed 文献 · Eur Radiol · 2018-06-06

研究纳入50例接受奥曲肽长效可重复剂型(LAR)治疗的高分化晚期胃肠胰神经内分泌肿瘤(GEP-NET)患者,基于基线与随访胸腹盆CT,用ROC分析和Kaplan-Meier法确定判断无进展生存(PFS)获益的最佳早期阈值。结果显示最佳阈值为靶病灶最长径之和变化(ΔSLD)-10%,敏感度85.7%、特异度80%;达此阈值者19例为应答者、31例为非应答者,中位PFS分别为20.2个月与7.6个月(HR 2.66,95%CI 1.32-5.36)。结论认为肿瘤缩小10%是奥曲肽LAR治疗晚期GEP-NET的可靠早期应答预测指标。

要点

  • 奥曲肽LAR治疗高分化晚期GEP-NET时,ΔSLD -10%为区分PFS获益的最佳早期阈值。
  • 该阈值下敏感度85.7%、特异度80%,19例为应答者、31例为非应答者。
  • 应答者中位PFS 20.2个月 vs 非应答者7.6个月(HR 2.66,95%CI 1.32-5.36)。

核心结论

  • 肿瘤缩小10%(ΔSLD -10%)是奥曲肽LAR治疗晚期GEP-NET的可靠早期应答预测指标。

研究设计与样本

  • 研究纳入50例接受奥曲肽LAR治疗的高分化晚期GEP-NET患者,行基线与随访胸腹盆CT,采用ROC分析与Kaplan-Meier法确定区分PFS获益的最佳阈值。

诊断标准与关键数值

  • 确定奥曲肽LAR应答的最佳阈值为ΔSLD -10%,敏感度85.7%、特异度80%;该阈值下19例为应答者、31例为非应答者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To identify a reliable early indicator of deriving progression-free survival (PFS) benefit in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR).

METHODS: We investigated the images of 50 patients with well-differentiated advanced GEP-NETs treated with LAR octreotide and underwent baseline and follow-up thoracic, abdominal, and pelvic computed tomography. Receiver-operating characteristic (ROC) analysis and the Kaplan-Meier method were used to identify the optimal threshold to distinguish between those with and without significant improvement of PFS.

RESULTS: The optimal threshold for determining a response to octreotide LAR was -10% ΔSLD, with a sensitivity and specificity of 85.7% and 80%, respectively. At this threshold, 19 patients were responders and 31 were non-responders; the median PFS was 20.2 and 7.6 months in responders and non-responders (hazard ratio, 2.66; 95% confidence interval, 1.32-5.36).

CONCLUSION: A 10% shrinkage in tumor size is an optimal early predictor of response to octreotide LAR in advanced GEP-NETs.

KEY POINTS: • Octreotide LAR can significantly prolong PFS among patients with well-differentiated advanced GEP-NETs. • No optimal tumor size-based response criteria are reported in GEP-NETs with octreotide. • Ten percent tumor shrinkage is a reliable indicator of the response to octreotide for advanced GEP-NETs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Luo Y, Chen J, Shen B, et al. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? Eur Radiol. 2018. PMID: 29876704. doi:10.1007/s00330-018-5512-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。